Shanghai Pharma (601607.SH): Isavuconazole Sulfate Active Pharmaceutical Ingredient Approved for Market Launch

Stock News01-13

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shang Pharma Kangli (Changzhou) Pharmaceutical Co., Ltd., recently received a notification of approval for the market application of the Isavuconazole Sulfate active pharmaceutical ingredient from the National Medical Products Administration.

The approval, with certificate number 2025YS01127, grants permission for the commercial production of the ingredient. This signifies that the API complies with the relevant regulations for domestic pharmaceutical registration and is cleared for sale in the Chinese market.

Furthermore, the approval of the Isavuconazole Sulfate API provides valuable experience for the company's future initiatives in API registration and development. The aforementioned matter is not expected to have a significant impact on the company's current operating performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122531724?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 15:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122531724","market":"hk","top_or_hot":-1,"title":"Shanghai Pharma (601607.SH): Isavuconazole Sulfate Active Pharmaceutical Ingredient Approved for Market Launch","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shang Pharma Kangli (Changzhou) Pharmaceutical Co., Ltd., recently received a notification of approval for the market application of the Isavuconazole Sulfate active pharmaceutical ingredient from the National Medical Products Administration.</p>\n<p>The approval, with certificate number 2025YS01127, grants permission for the commercial production of the ingredient. This signifies that the API complies with the relevant regulations for domestic pharmaceutical registration and is cleared for sale in the Chinese market.</p>\n<p>Furthermore, the approval of the Isavuconazole Sulfate API provides valuable experience for the company's future initiatives in API registration and development. The aforementioned matter is not expected to have a significant impact on the company's current operating performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharma (601607.SH): Isavuconazole Sulfate Active Pharmaceutical Ingredient Approved for Market Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharma (601607.SH): Isavuconazole Sulfate Active Pharmaceutical Ingredient Approved for Market Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-13 15:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shang Pharma Kangli (Changzhou) Pharmaceutical Co., Ltd., recently received a notification of approval for the market application of the Isavuconazole Sulfate active pharmaceutical ingredient from the National Medical Products Administration.</p>\n<p>The approval, with certificate number 2025YS01127, grants permission for the commercial production of the ingredient. This signifies that the API complies with the relevant regulations for domestic pharmaceutical registration and is cleared for sale in the Chinese market.</p>\n<p>Furthermore, the approval of the Isavuconazole Sulfate API provides valuable experience for the company's future initiatives in API registration and development. The aforementioned matter is not expected to have a significant impact on the company's current operating performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1122531724","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122531724","pubTimestamp":1768290857,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shang Pharma Kangli (Changzhou) Pharmaceutical Co., Ltd., recently received a notification of approval for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK0097":"医药电商","BK0184":"上海国资改革","BK0099":"上海本地重组","BK0028":"国家队","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0209":"零售","02607":"上海医药","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"上海医药（601607.SH）：硫酸依沙康唑活性药物成分获批上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shang Pharma Kangli (Changzhou) Pharmaceutical Co., Ltd., recently received a notification of approval for the market application of the Isavuconazole Sulfate active pharmaceutical ingredient from the National Medical Products Administration.\nThe approval, with certificate number 2025YS01127, grants permission for the commercial production of the ingredient. This signifies that the API complies with the relevant regulations for domestic pharmaceutical registration and is cleared for sale in the Chinese market.\nFurthermore, the approval of the Isavuconazole Sulfate API provides valuable experience for the company's future initiatives in API registration and development. The aforementioned matter is not expected to have a significant impact on the company's current operating performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122531724","isCrawlerRequest":true}